Drug Markets/Adalimumab-Adaz

Adalimumab-Adaz

1 NDC across 1 manufacturer|1 Generic,0 Brand

Adalimumab-Adaz is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.

▸ More about this market

In 2024, Medicare Part D spent $15 million on Adalimumab-Adaz across 4,540 claims for 1,411 beneficiaries.

Adalimumab-Adaz is available as 1 NDC from 1 manufacturer (1 generic, 0 brand), with NADAC prices from $1586.73 to $1586.73 per ML. Every pack size and labeler in this drug market is compared side-by-side below.

Total NDCs

1

1G / 0B

Manufacturers

1

competing in market

Price Spread

$1586.73 – $1586.73

per ML

7d Activity

10 flat

avg -0.0% WoW · of 1 NDCs

Market Price Trend

Monthly average NADAC per unit, split by generic and brand.

Manufacturer Breakdown

1 manufacturer producing ADALIMUMAB-ADAZ

Drug Portfolio

1 NDCs total, 1 shown

Drug Price 7d Change
ADALIMUMAB-ADAZ(CF) PEN 40 MG/0.4 ML
$1586.7323
per ML
-0.01%

Frequently Asked Questions

What is Adalimumab-Adaz used to treat?

Adalimumab-Adaz is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.

How much does Medicare spend on Adalimumab-Adaz?

In 2024, Medicare Part D spent $15 million on Adalimumab-Adaz across 4,540 claims for 1,411 beneficiaries.

How many Adalimumab-Adaz products are on the market?

The Adalimumab-Adaz drug market contains 1 NDC from 1 manufacturer — 1 generic and 0 brand products.

What is the price range for Adalimumab-Adaz?

NADAC reference prices for Adalimumab-Adaz range from $1586.7323 to $1586.7323 per ML.

Which manufacturers make Adalimumab-Adaz?

1 manufacturer lists Adalimumab-Adaz in NADAC. Ranked by number of NDCs, the largest are Sandoz Inc. (1).

How has the price of Adalimumab-Adaz changed recently?

Over the past 7 days, 0 Adalimumab-Adaz NDCs rose and 1 fell, with a market-wide average change of -0.0%.